The Scan You Paid For: Who Owns the Follow-Up?

Private health scanning has moved from a niche luxury to a familiar high-street product. Full-body MRI packages, often marketed as a 'health MOT' or a 'peace of mind' scan, are advertised to asymptomatic adults across the UK. Most people who pay will receive a reassuring report. A minority will receive something more awkward: an incidental finding — a nodule, cyst, lesion or borderline measurement that was not the reason for the scan and may never cause harm. The clinical question is not whether the finding is interesting. It is who owns the next step.

In 2026, this is no longer a fringe issue for general practice. It is a routine consequence of a consumer imaging market that sits alongside, but not inside, NHS pathways. The NHS has a duty to consider clinically relevant information about registered patients. It does not have an automatic obligation to adopt every privately generated surveillance recommendation. The gap between those two positions is where patients, GPs and private providers can all come unstuck.

An incidentaloma is a finding without a question

The term incidentaloma is used for a lesion discovered during imaging performed for another reason. Better imaging and wider scanning increase the number of such findings. Many are benign and require no action. Others, such as certain lung nodules, adrenal lesions or renal masses, may need time-bound investigation. The difficulty is that a private scan often arrives without the clinical context that NHS imaging would normally carry: why the scan was done, what the pre-test probability was, what the patient was told, and what the provider intended to happen next.

A finding is not the same as a diagnosis. Nor is a recommendation for follow-up the same as a plan that someone has agreed to deliver. Primary care teams are skilled at managing uncertainty, but they cannot manufacture capacity or accountability from a report alone. The first task is to separate a clinically meaningful finding from a commercially generated loose end.

Where responsibility sits after the report

Before a private provider offers a scan, it should be able to name the clinician who will review the images, the arrangements for communicating unexpected findings, and the route for further investigation if something is found. A report that states 'GP to arrange follow-up' transfers work without negotiation. That is not a safe handover. It is an assumption.

Patients should leave the provider with a clear written summary, access to their images, and an explanation of any recommended next step. If the provider recommends surveillance, it should say who will provide it, on what timescale, and at whose cost. If the provider will not arrange follow-up, that should be stated before payment, not discovered afterwards. Sharing information with the patient's GP should be routine and should be explained in advance.

General practice should not refuse to look at relevant information, but it should also not accept an open-ended private pathway by default. A GP can assess the finding, consider symptoms and risk factors, and decide whether NHS action is indicated. That is clinical triage, not an assumption of ownership for every scan sold on the high street.

A practical triage sequence for primary care

A consistent approach helps reduce both over-referral and missed serious disease. Five steps are useful.

• Confirm provenance and completeness. Check who reported the scan, whether images are available, what technique was used, and whether the patient has been told the result. A report without images or a named responsible clinician is a weak basis for NHS action.
• Take a focused history. Ask about symptoms, risk factors, previous imaging and family history. An incidental finding in a symptomatic patient is not truly incidental. New pain, weight loss, bleeding or unexplained change should alter the threshold for action.
• Apply an established pathway where one exists. Use national guidance, local cancer pathways or specialist advice for findings with recognised surveillance criteria. Avoid inventing a bespoke follow-up interval when a validated pathway is available.
• Prioritise by time sensitivity and likely harm. The question is not simply whether a finding is abnormal, but whether delay could change the outcome. A small likely-benign cyst can be safety-netted; a lesion with features suggesting malignancy needs timely specialist assessment.
• Document the decision and the safety net. Record what was reviewed, what was discussed with the patient, what action was taken, and what should prompt re-contact. If the finding is not being adopted into NHS follow-up, say so clearly and explain why.

This sequence does not resolve every case. Some findings will need specialist advice, and some patients will need support to understand why a private scan recommendation is not automatically an NHS entitlement. But a structured response is better than an inbox-driven one, where the loudest report or the most anxious patient sets the clinical priority.

Consent before the scan, not after

Private providers should make several points explicit before a customer pays. The scan is not an NHS screening programme and has not been commissioned on population criteria. Incidental findings are a known consequence of imaging, not a rare malfunction. The provider's responsibility for follow-up should be described in plain terms, including any additional costs. The limits of the scan should be stated, including the fact that a normal result does not exclude all disease. The patient should also know how images and reports will be shared with their GP, and what will happen if a finding needs urgent attention.

Consent materials that omit these points are not informed consent in any meaningful sense. They are sales copy with a disclaimer attached. The ethical standard is not simply whether the patient signed. It is whether they understood what they were buying and what they were not.

Making the handover work

A workable handover has a small number of features: a named private clinician, accessible images, a concise summary, an explicit follow-up proposal, and patient consent to share information. Primary care can then triage on clinical grounds rather than administrative guesswork. Where local arrangements exist for private imaging queries, they should be used. Where they do not, the default should be a documented clinical decision, not an endless chain of requests for someone else to take responsibility.

The incidentaloma backlog is not a reason to discourage all private imaging. It is a reason to be honest about the handover. A scan paid for privately can still produce a finding that matters to the NHS. The least we can do is make sure that when it does, the next step has an owner.